AbbVie has obtained approval from the European Commission for ELAHERE® (mirvetuximab soravtansine) to treat platinum-resistant ovarian cancer.

Biosion has signed a global exclusive licensing deal with Aclaris Therapeutics for two promising immunology products that could be first-in-class and best-in-class.

Capstan Therapeutics showcases preclinical findings on its primary in vivo CAR-T candidate, CPTX2309, during the ACR Convergence 2024 event.

Neurogene has provided an update regarding its ongoing Phase 1/2 open-label clinical study assessing the NGN-401 gene therapy.

Adicet Bio reports the dosing of the initial lupus nephritis patient in its Phase 1 trial of ADI-001 for autoimmune conditions.

Arrowhead Pharmaceuticals has filed a New Drug Application with the U.S. FDA for plozasiran to treat Familial Chylomicronemia Syndrome.

Seismic Therapeutics showcases new preclinical findings for S-4321, a next-gen bifunctional agonist antibody that targets PD-1 and FcγRIIb.

The trial tests TGN-S11 alone and in combination with Keytruda® (pembrolizumab) for stage 4 cancer patients associated with Human Papillomavirus.

Samsung Bioepis and Biogen have obtained approval from the European Commission (EC) for their Aflibercept biosimilar, named OPUVIZ.

Bluejay Therapeutics, has revealed new findings from its Phase 2 trial of BJT-778.

Acepodia has received FDA approval for the Investigational New Drug Application of ACE1831 to treat IgG4-related disease.

Syndax has received FDA approval for Revuforj® (revumenib), marking it as the first menin inhibitor for treating adults and children with relapsed or refractory acute leukemia featuring a KMT2A translocation.